Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer for which there is a critical need to identify novel therapeutic targets.
Herein we define PSGL-1 as a checkpoint inhibitor using a syngeneic orthotopic model of PDAC.
As with PDAC patients, CD8
